• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected

    6/13/24 3:29:48 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IGC alert in real time by email

    Anson Funds agreed to a $2.25 million settlement with the Securities and Exchange Commission (SEC) over a secret relationship with a short seller affecting two cannabis companies. The SEC found that while Anson Funds disclosed its short position strategy to investors, it did not reveal its collaboration with an activist short publisher, which remains undisclosed.

    The Scheme

    The SEC detailed that Anson Funds would establish a short position before the release of negative reports by the short seller, reported Bloomberg. These reports often led to a decrease in the target companies’ stock prices, allowing Anson Funds to profit from the drop. The events happened in 2018, and the involved cannabis companies included Namaste Technologies Inc. (now Lifeist Wellness Inc.) (OTC:LFSWD) and India Globalization Capital (now IGC Pharma Inc.) (NYSE:IGC).

    The scheme involved coordinated efforts where Anson Funds paid the short seller a share of its profits through third-party invoices for non-existent research services, thus masking the true nature of the transactions.

    To learn about cannabis finances and the role of the SEC in the space, join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off.

    Legal Repercussions

    The SEC accused Anson Funds of failing to inform investors about this arrangement, rendering its statements about its short-selling strategy misleading. The SEC also noted discrepancies in the firm’s record-keeping related to these transactions. Consequently, Anson Funds agreed to pay a civil penalty of $1.25 million, and Anson Advisors Inc. in Toronto agreed to a $1 million penalty.

    Anson Funds defended its actions by stating that its involvement benefited investors and the broader market by highlighting overvalued stocks. However, the SEC criticized the fund for omitting crucial details in its communications with prospective investors and for inaccurately recording payments, thus violating the Advisers Act compliance rules.

    Gains for Anson Funds

    Bloomberg reported that Anson Funds generated over $4 million in gains from this move. The payment to the short seller, made through a third party, amounted to $1.1 million. This investigation is part of a wider effort by U.S. authorities to examine relationships between hedge funds and bearish researchers, which began three years ago and involves more than 50 stocks. Thus, the sentence inaugurates what can be the first of many scrutinies by the SEC and the Department of Justice (DOJ) into illegal short-selling involving hedge funds and research firms.

    Get the next $IGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IGC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IGC
    SEC Filings

    View All

    IGC Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - IGC Pharma, Inc. (0001326205) (Filer)

    3/30/26 5:43:01 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-KT filed by IGC Pharma Inc.

    10-KT - IGC Pharma, Inc. (0001326205) (Filer)

    3/18/26 4:02:27 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - IGC Pharma, Inc. (0001326205) (Filer)

    1/2/26 4:02:27 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moran James P bought $200,000 worth of shares (588,235 units at $0.34) (SEC Form 4)

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    9/27/24 4:05:18 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

    POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o

    1/21/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

    POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery. They will also discuss key upcoming milestones, including new clinical trial launches, preclinical developments, and efforts to broaden the Compa

    1/13/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

    Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.To accelerate enrollment across all clinical sites, IGC Pharma has implemented an innovative recruitment campaign leveraging geofencing

    1/8/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Prins Richard K

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:50 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mukunda Ram

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:29 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moran James P

    4 - IGC Pharma, Inc. (0001326205) (Issuer)

    4/6/26 4:02:01 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Leadership Updates

    Live Leadership Updates

    View All

    IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

    POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries. As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare o

    1/21/25 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Announces Results of its 2024 Annual Stockholders Meeting

    IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the "Annual Meeting"), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 28, 2024, were entitled to and requested to vote at the Annual Meeting. At the Annual Meeting, all of the following proposals were approved by the requisite vote of the stockholders: (i) the election of Mr. Richard Prins and Mr. Terry Lierman to the Company's board of directors to serve as Cla

    8/26/24 7:00:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

    IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE:IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors. Mr. Lierman is currently Co-Chair of the Board of Advisors at the Institute of Human Virology (IHV), a center in the U.S. focused on accelerating the discovery of diagnostics and therapeutics for deadly viral and immune disorders and a member of the Board of Visitors at the La Follette School of Public Affairs at the University of Wisconsin, his alma mater. Terry founded the Children's Research Institute, one of America's top children's research programs, the Pancreatic Cancer Action Network (PanCAN), and the National

    3/12/24 3:00:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Financials

    Live finance-specific insights

    View All

    IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

    POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap

    11/14/24 8:30:00 AM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Pharma Reports First Quarter Fiscal 2025 Results

    IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company's Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic candidate addressing agitation in Alzheimer's disease. On April 16, 2024, the Company announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two compared to placebo. On May 28, 2024, the Comp

    8/8/24 9:30:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

    IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Full Fiscal Year Highlights In March 2024, the Company announced positive interim results from its ongoing Phase 2 trial for IGC-AD1. The interim data have shown promising results in reducing Alzheimer's agitation, which is a major challenge for patients and their caregivers alike. This development marks a significant step forward in the fight against Alzheimer's and brings hope to millions of people affected by this devastating disease. In January 2024, the Company announced details about its dru

    6/24/24 7:30:00 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by IGC Pharma Inc.

    SC 13D/A - IGC Pharma, Inc. (0001326205) (Subject)

    8/14/24 4:23:18 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by IGC Pharma Inc.

    SC 13D - IGC Pharma, Inc. (0001326205) (Subject)

    5/21/24 9:20:27 PM ET
    $IGC
    Biotechnology: Pharmaceutical Preparations
    Health Care